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Abstract Mitochondrial deoxyguanosine kinase (dGK) cata-
lyzes the initial phosphorylation of purine deoxynucleosides.
Mutations in the dGK gene leading to de¢ciency in dGK activity
is one of the causes of severe mitochondrial DNA depletion
diseases. We used site-directed mutagenesis to introduce the
clinically observed genetic alterations in the dGK gene and char-
acterized the recombinant enzymes. The R142K enzyme had
very low activity with deoxyguanosine and no activity with de-
oxyadenosine. The E227K mutant enzyme had unchanged Km
values for all its substrates but very low Vmax values. C-terminal
truncated dGK proteins were inactive. These results may help to
de¢ne the role of dGK in mitochondrial DNA (mtDNA) pre-
cursor synthesis.
- 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
The synthesis of mitochondrial DNA (mtDNA) is not cell
cycle regulated and a constant supply of deoxyribonucleoside
triphosphate (dNTP) is vital for the maintenance of mito-
chondrial integrity. However, there is apparently no de novo
nucleotide biosynthesis in the mitochondria. Nucleotides re-
quired for mtDNA replication are either synthesized by the
salvage enzymes in the mitochondria or imported from the
cytosol [1,2]. Mitochondrial deoxyguanosine kinase (dGK)
and thymidine kinase 2 (TK2) are the two enzymes which
are responsible for the initial rate-limiting phosphorylation
of all the four deoxynucleosides in the synthesis of precursors
for mtDNA replication. Both dGK and TK2 are constitu-
tively expressed in all tissues and the levels of these two en-
zymes are believed to correlate to the number of mitochondria
[1,2]. In resting cells and terminally di¡erentiated cells the de
novo synthesis of deoxynucleotides is not present nor is the
salvage synthesis of thymidine nucleotides via thymidine ki-
nase 1. In this case the import of nucleotides from the cytosol
to the mitochondria is not possible, and the salvage of deoxy-
nucleosides by dGK and TK2 is the only source of DNA
precursors.
Mitochondrial DNA depletion syndrome (MDS) is a clin-
ically heterogeneous group of disorders characterized by a
reduction in mtDNA copy number. Primary mtDNA deple-
tion is inherited as an autosomal recessive trait and may a¡ect
single organs, typically muscle or liver, or multiple tissues [3].
Recently, the myopathic form of MDS has been ascribed to
mutations in the TK2 gene [4], and the hepatocerebral form
has been ascribed to mutations in the dGK gene [5]. Since
then, several additional mutations have been identi¢ed in ei-
ther the TK2 or the dGK genes of patients presenting with
MDS [6^10].
In order to understand the mechanism resulting in the dis-
ease phenotypes caused by dGK de¢ciency we used site-di-
rected mutagenesis to introduce the mutations, base pair de-
letions and insertion found in the patients reported recently
[5^7]. The recombinant dGK enzymes were expressed in Es-
cherichia coli, puri¢ed and characterized with the most impor-
tant substrates.
2. Materials and methods
2.1. Materials
Radiolabelled nucleosides [8-3H]-2P-deoxyguanosine (3H-dGuo; 5.9
Ci/mmol) and [2, 8-3H]-2P-deoxyadenosine (3H-dAdo; 17.1 Ci/mmol)
were purchased from Moravek biochemicals Inc. Non-radioactive nu-
cleosides were from Sigma.
2.2. Mutagenesis, expression and puri¢cation
Point mutations were introduced by a polymerase chain reaction
(PCR)-based method as described [11] and the PCR fragments which
contained the desired mutations were subcloned into the pET-9d vec-
tor (Novagen) as was wild-type dGK cDNA [12]. The mutations were
veri¢ed by sequencing using the BigDye1 terminator kit and ABI
Prism 310 system (Perkin-Elmer).
The plasmids which contain the desired mutations were trans-
formed into the BL21 (DE3) pLysS bacteria (Novagen). All mutant
dGK enzymes were expressed and puri¢ed by the same procedure as
the wild-type dGK as described previously [13] with the exception that
no adenosine triphosphate (ATP) was added in the elution bu¡er.
Aliquots of puri¢ed enzymes were analyzed by 12% sodium dodecyl
sulfate^polyacrylamide gel electrophoresis (SDS^PAGE) and protein
concentration was determined by Bio-Rad protein assay using bovine
serum albumin (BSA) as standard.
2.3. Enzyme assay
dGK activity was determined by using [3H]dGuo or [3H]dAdo as
substrates as previously described [12,14]. The standard reaction mix-
ture contains 50 mM Tris/HCl, pH 7.6, 2 mM ATP, 2 mM MgCl2, 0.5
mg/ml BSA, 5 mM dithiothreitol and 50 WM labelled deoxynucleoside
and puri¢ed enzyme. For the measurement of the kinetic constants a
wide concentration range of each substrate was used. The data were
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analyzed by the Sigma Plot Enzyme Kinetic Module version 1.1 (SPSS
Inc.).
3. Results
3.1. Genetic alteration in the dGK gene of patients with MDS
To date there are ¢ve reported alterations in the dGK gene,
including deletions, point mutations or base pair insertion,
which caused MDS in patients with hepatic failure as summa-
rized in Table 1. Four of these alterations resulted in prema-
ture stop and truncation of the dGK proteins and the a¡ected
individuals had severe liver diseases and died at early infancy.
The point mutations found in a compound heterozygous pa-
tient had milder e¡ects and the patient survived after liver
transplantation [5^7]. In order to correlate the disease pheno-
type to dGK enzyme de¢ciency we used site-directed muta-
genesis to introduce these genetic alterations in the dGK gene
and expressed the recombinant enzymes in E. coli. They were
subsequently puri¢ed and characterized with regard to sub-
strate speci¢city and catalytic e⁄ciency.
3.2. Truncations at the C-terminal end of the dGK proteins
A GATT (nucleotides 763^766) duplication in exon 7 re-
sulted in a 22 amino acid deletion at the C-terminus. This
C-terminal truncated dGK protein was expressed in E. coli
and puri¢ed. The recombinant protein was inactive. To verify
the functional importance of the C-terminal domain of dGK,
two other C-terminal deletion mutants were generated in the
same way with 11 and 18 amino acid truncations. Both re-
combinant enzymes were inactive. These results suggested that
the C-terminal domain is indispensable for enzyme activity.
Thus, one can predict that other truncated dGK proteins
(Table 1) are most likely inactive.
3.3. Properties of the R142K mutant enzyme
Recombinant R142K enzyme had very low activity with
dGuo and no detectable activity with dAdo. With dGuo as
substrate the Km value was about 30-fold higher and the Vmax
value was about 20-fold lower as compared to wild-type dGK
(Table 2). Therefore, the e⁄ciency for dGuo phosphorylation
by the R142K mutant enzyme was only about 0.2% of the
wild-type enzyme. The ATP/MgCl2 dependence was also ex-
amined, the Km value was about 11-fold higher and the Vmax
value was about 20-fold lower as compared with the wild-type
enzyme (Table 3).
3.4. Properties of the E227K mutant enzyme
Recombinant E227K enzyme had low activity with both
dGuo and dAdo. The Km values for dGuo, dAdo and ATP/
MgCl2 with either dGuo or dAdo as the ¢xed substrate were
similar to that of the wild-type dGK (Tables 2 and 3). How-
ever, the Vmax values were much lower; 27-, 22-, 31- and 58-
fold lower respectively, as compared with the wild-type en-
zyme (Tables 2 and 3). Thus, the e⁄ciencies for dGuo and
dAdo phosphorylation were only 2.8 and 5.5% of the wild-
type dGK (Table 2).
4. Discussion
MDS is characterized as quantitative reduction of mtDNA
copy number, which impairs the synthesis of respiratory chain
components [3]. The synthesis of mtDNA is carried out by
several nuclear encoded proteins, e.g. DNA polymerase Q.
However, mtDNA copy number has been suggested to be
controlled by the mitochondrial dNTP pools [15]. De¢ciency
in either dGK or TK2 activity would impair the synthesis of
DNA precursors in the mitochondria and lead to imbalance
Table 1
Summary of the known genetic defects in the dGK gene
Mutations Outcome (dGK enzyme alteration) Disease onset and survival
A (nucleotide 204) deletiona frame shift and premature stop at 80 amino acids from birth to 6 months, death before 1 year of age
C (nucleotide 313) to Tb premature stop at 105 amino acids From birth, died at 5 months of age
GT (nucleotides 609^610) deletionc premature stop at 213 amino acids from 2 months, died at 6 months of age
GATT (nucleotides 763^766)
duplicationc
premature stop at 255 amino acids from 2 months, died at 5 months of age
G (nucleotide 425) to Ac point mutation R142K this patient was compound heterozygous
G (nucleotide 679) to Ac point mutation E227K from 6 months, underwent liver transplantation at





Kinetic parameters of wild-type and mutant dGK enzymes with phosphate acceptors
dGuo dAdo
Km (WM) Vmax (units) E⁄ciency (Vmax/Km) Km (WM) Vmax (units) E⁄ciency (Vmax/Km)
Wild-typea 4 43 10.8 (100) 467 429 0.9 (100)
R142K 123L 1 2.0L 0.01 0.02 (0.19) NA NA
E227K 5.2L1 1.6L 0.1 0.3 (2.8) 414L 54 19.6L 1.6 0.05 (5.5)
For the measurement of phosphate acceptor constants the dGuo or dAdo concentration was varied (4^505 WM) and the concentration of ATP/
MgCl2 was constant (2 mM). One unit is de¢ned as the formation of 1 nmol dGMP (or dAMP) per min per mg protein. Data in parentheses
are relative values as compared with the wild-type enzyme.
NA: no detectable activity.
aData from [13].
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of dNTP pools, which eventually would cause mtDNA deple-
tion.
Human dGK has been characterized enzymatically
[12,13,16] and the three-dimensional (3-D) structure is known
[17]. The C-terminal K-helix number 9 (K9) of dGK is part of
the phosphate donor binding site and therefore plays an
important role in enzyme catalysis [17,18]. Deletion of the
C-terminal 22 amino acid residues resulted in an incomplete
phosphate donor binding site. Indeed the C-terminal 22 amino
acid deletion mutant is devoid of enzyme activity, which dem-
onstrated the importance of K9 in enzyme catalysis. Addition-
ally, deletions of part of K9, e.g. 11 and 18 amino acid trun-
cations, resulted in virtually inactive enzymes. Therefore, one
may assume that mutations that caused premature stops in
the dGK gene would lead to dGK de¢ciency in the tissues of
the a¡ected individuals.
Two point mutations, i.e. R142K and E227K, have also
been identi¢ed in patient with MDS [6]. These mutant en-
zymes were constructed and characterized. Both residues,
R142 and E227, are conserved among the family of deoxynu-
cleoside kinases, including dGK and TK2. R142 is located
close to the active site but E227 is not. Residue E227 is lo-
cated in K8. It forms hydrogen bonds with residues Y191 and
Q193 in L4 and appears not to interact directly with any of
the substrates [6,17,18]. Experimental results with recombi-
nant E227K enzyme indicated no alteration of substrate bind-
ing capacity as revealed by the Km values but it showed a
severely decreased catalytic rate. The hydrogen bonds between
K8 and L4 probably stabilize the enzyme active site structure.
The so-called LID region is a connecting loop between K7 and
K8 [17,18] and it is believed that the LID structure undergoes
dynamic movements during catalysis. Substitution of gluta-
mate with a lysine residue in this position, E227K, introduced
an opposite charge in the area and also a loss of two hydrogen
bonds to Y191 and Q193. Such a disturbance may impair
enzyme function which is re£ected in low catalytic rates.
In contrast to the E227K mutation, the R142K mutation
a¡ected the binding of all the substrates; the mutant enzyme
had apparently lost its ability to phosphorylate dAdo and also
showed very low e⁄ciency for dGuo phosphorylation. In the
dGK 3-D structure R142 is situated in the active site, and
interacts by a hydrogen bond with the 5P-OH group of the
nucleoside [17]. The other amino acid residue that forms a
hydrogen bond with the 5P-OH group is E70 and their con-
tacts with the base largely determine the substrate speci¢city
(Fig. 1) [17,18]. The amino group of K142 is between 1 and
2 AP further away from the 5P-OH group as compared with
R142 (Fig. 1). This clearly diminished the catalytic capacity of
dGK, possibly by not being able to stabilize the transition
state of the reaction intermediates. The R142K mutant is
thus providing a start point for detailed studies of the reaction
mechanism for this class of deoxynucleoside kinases.
Translation of mtDNA-encoded proteins is dependent on
mtDNA copy number since the expression of mtRNA poly-
merase is directly correlated to mtDNA copy number [19].
Therefore, mtDNA depletion will result in a reduced amount
of mtDNA-encoded enzymes and thus low respiratory activity
that, in turn, leads to low ATP content. In the in vivo situa-
tion the combination of a poor dGK enzyme and low ATP
concentration may result in very low deoxyadenosine triphos-
phate (dATP) and deoxyguanosine triphosphate pools as
compared with deoxythymidine triphosphate and deoxycyti-
dine triphosphate pools. Liver, heart, skeletal muscle and
Fig. 1. A model of the dGK structure with the active site residues
Glu70 and Arg142 or Lys142 that are in close contact with the 5P-
OH group of the substrate (deoxyguanosine: dG). The model is
based on the structure of dGK with bound ATP [17], where the ad-
enine base and deoxyribose have been substituted by dG and the
mutant Lys142 has been aligned to ¢t the position of Arg142 as
close as possible. Color indications: carbon atoms are in black, oxy-
gen atoms are in red, nitrogen atoms are in blue except that in
Arg142 the nitrogen atoms are in yellow for comparison.
Table 3
Kinetic parameters with ATP/MgCl2 for both wild-type and mutant dGK enzymes
dGuo (100 WM as acceptor) dAdo (100 WM as acceptor)
Km (WM) Vmax (units) E⁄ciency (Vmax/Km) Km (WM) Vmax (units) E⁄ciency (Vmax/Km)
Wild-type 8.5 L 1 22L0.6 2.6 (100) 269L 28 215L 7 0.80 (100)
R142K 97.4L 1 1.1L 0.01 0.2 (7.7) NA NA
E227K 14L 2 0.68L0.01 0.05 (1.9) 242L 40 3.7 L 0.2 0.02 (2.5)
For the measurement of phosphate donor constant ATP/MgCl2 was varied (20^2000 WM) and dGuo or dAdo was at ¢xed concentration. One
unit is de¢ned as the formation of 1 nmol dGMP (or dAMP) per min per mg protein. Data in parentheses are relative values as compared
with the wild-type enzyme.
NA: no detectable activity.
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brain are among the most energy-dependent tissues of the
body and therefore they are vulnerable to mtDNA depletion,
most likely through the operation of this vicious circle.
The residual dGK activity seems to play a crucial role in
disease progression. Patients who completely lacked dGK ac-
tivity had in common early onset of the disease and died at
earlier infancy. The patient who was compound heterozygous
with point mutations, e.g. R142K and E227K, had about 27%
dGK activity as compared with control individuals [6]. Even
though the mutant enzymes had very low activity, the onset of
the symptoms was later as compared with other cases and the
symptoms were milder.
The establishment of a correlation between the dGK activ-
ity levels and disease development may encourage develop-
ment of therapeutic regimes to help patients to suppress the
disease. Organ transplantation or gene therapy are among the
possible approaches but they may not be available to all af-
fected individuals. Therapies which stimulate nucleotide bio-
synthesis either via the de novo or the salvage pathway to
increase the cellular dNTP pools may increase the chance to
delay disease development. In line with this assumption, it was
recently reported that partial reversion of mtDNA depletion
due to dGK de¢ciency could be obtained by providing resting
patient ¢broblast with deoxyadenosine monophosphate
(dAMP) or deoxyguanosine monophosphate added to the cul-
ture medium [20].
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